Louisiana State Employees Retirement System purchased a new stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX – Free Report) during the first quarter, HoldingsChannel.com reports. The firm purchased 15,200 shares of the company’s stock, valued at approximately $1,511,000.
Several other institutional investors and hedge funds have also bought and sold shares of TMDX. Harvest Fund Management Co. Ltd purchased a new position in shares of TransMedics Group during the third quarter valued at approximately $29,000. Allworth Financial LP increased its position in shares of TransMedics Group by 74.3% during the third quarter. Allworth Financial LP now owns 265 shares of the company’s stock valued at $30,000 after buying an additional 113 shares during the period. LOM Asset Management Ltd bought a new position in TransMedics Group in the third quarter worth about $34,000. FNY Investment Advisers LLC purchased a new stake in TransMedics Group in the third quarter worth about $34,000. Finally, Parallel Advisors LLC lifted its holdings in TransMedics Group by 42.1% in the fourth quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock worth $34,000 after buying an additional 83 shares during the period. Hedge funds and other institutional investors own 99.67% of the company’s stock.
Wall Street Analysts Forecast Growth
Several analysts have weighed in on TMDX shares. Stifel Nicolaus lifted their price objective on TransMedics Group from $75.00 to $80.00 and gave the company a “hold” rating in a research report on Thursday, June 18th. Wall Street Zen lowered TransMedics Group from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. TD Cowen restated a “buy” rating and issued a $120.00 target price on shares of TransMedics Group in a research note on Wednesday. Oppenheimer lowered TransMedics Group from an “outperform” rating to a “market perform” rating in a research report on Wednesday, May 6th. Finally, Needham & Company LLC decreased their price objective on TransMedics Group from $174.00 to $142.00 and set a “buy” rating for the company in a report on Wednesday, May 6th. Six analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $134.50.
Insider Buying and Selling
In related news, Director Thomas J. Gunderson sold 9,624 shares of the stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $75.06, for a total transaction of $722,377.44. Following the sale, the director directly owned 16,642 shares of the company’s stock, valued at approximately $1,249,148.52. This represents a 36.64% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 6.90% of the company’s stock.
TransMedics Group Stock Up 1.5%
TMDX stock opened at $68.86 on Friday. TransMedics Group, Inc. has a twelve month low of $60.10 and a twelve month high of $156.00. The company has a quick ratio of 6.19, a current ratio of 6.74 and a debt-to-equity ratio of 1.70. The firm has a market cap of $2.38 billion, a PE ratio of 15.65 and a beta of 1.89. The business has a 50 day moving average of $75.95 and a 200 day moving average of $108.51.
TransMedics Group (NASDAQ:TMDX – Get Free Report) last released its earnings results on Tuesday, May 5th. The company reported $0.30 EPS for the quarter, missing the consensus estimate of $0.62 by ($0.32). TransMedics Group had a return on equity of 22.38% and a net margin of 27.04%.The company had revenue of $173.93 million during the quarter, compared to the consensus estimate of $174.44 million. During the same period last year, the firm posted $0.70 earnings per share. The company’s revenue was up 21.2% compared to the same quarter last year. On average, research analysts forecast that TransMedics Group, Inc. will post 1.92 EPS for the current fiscal year.
About TransMedics Group
TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.
TransMedics currently markets two commercially available OCS platforms.
Featured Stories
- Five stocks we like better than TransMedics Group
- Shorting the Grid: Bloom Energy’s $25B AI Power Play
- SanDisk’s Volatility May Be Telling Bulls What They Want to Hear
- Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon
- 3 Dividend ETFs Built for Stability in a Volatile Market
Want to see what other hedge funds are holding TMDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransMedics Group, Inc. (NASDAQ:TMDX – Free Report).
Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.
